MANAGEMENT OF HIV POSITIVE PREGNANCIES IN ONTARIO: CURRENT STATUS

Main Article Content

Sarabjit Gahir
Gregory J Anger
Michael Ibrahim
Stanley Read
Micheline Piquette-Miller

Keywords

MTCT, HIV, pregnancy, anti-retroviral therapy

Abstract

Background


AIDS is one of the biggest health crises we face today. With nearly 20 million women infected with the virus that causes it, HIV, maternal transmission of HIV is increasingly becoming a serious concern and hindrance in stemming the proliferation of the disease. While an ever increasing number of pregnant women are being administered anti-retrovirals to mitigate the vertical transmission of the virus, little is known about the changing trends in the type of agents used and the duration of therapy.


 


Objectives


This paper attempts to identify any changes in the pattern of HIV management in pregnant women for the period of time spanning 1998 to 2005.


 


Methods


Data from the charts of 183 patients were reviewed. A retrospective, longitudinal and cross-sectional patient chart review was employed to obtain data. Parameters such as therapeutic management of HIV, class of drugs used and duration of treatment were assessed to identify any evolving patterns over the course of the study.


 


Results


It was seen that over time, the number of women receiving adequate therapeutic interventions has steadily increased. We also identified evolving trends in terms of the classes of anti-retrovirals employed and the duration of prophylaxis.


 


Conclusion


The strategies employed in the management of HIV positive pregnancies in Ontario, while evolving over time, were found to be in line with the guidelines in place. The information delivered by this study might enable the medical community to assess the progress in dealing with this challenge thus far and further fine tune the current strategy.

Abstract 70 | PDF Downloads 41

References

1. P.H.A.O. Canada. HIV and AIDS in Canada: Surveillance Report to June 30, 2006. 2006:1- 66.
2. Remis RS, Schiedel L, Fikre M, Liu J. Report on HIV/AIDS in Ontario 2005. O.M.o.H.a.L.-T. Care, Editor. 2007:1-192.
3. John GC, Nduati RW, Mbori-Ngacha DA, et al. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001;183(2):206-212.
4. Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. Aids 1997;11(4):437-44.
5. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr 2005;38(1):87-95.
6. Burdge DR, Money DM, Forbes JC, et al. Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ 2003;168(13):1683-8.
7. Brockleburst P. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type I--a meta-analysis of 15 prospective cohort studies. J Pediatr 1999;135(5):649.
8. Group, P.H.G.W. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-1- infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. In http://aidsinfo.nih.gov/ContentFiles/Perinatal GL.pdf. 2006:1-65.
9. UNICEF. Children and AIDS: A stocktaking report. 2007. UNICEF.
10. Bialkowska A, Bialkowski K, Gerschenson M, et al. Oxidative DNA damage in fetal tissues after transplacental exposure to 3'-azido-3'- deoxythymidine (AZT). Carcinogenesis 2000;21(5):1059-62.
11. Calamandrei G, Venerosi A, Branchi I, Valanzano A, Alleva E. Prenatal exposure to anti-HIV drugs. Long-term neurobehavioral effects of lamivudine (3TC) in CD-1 mice. Neurotoxicol Teratol 2000;22(3):369-79.
12. Chitnis S, Mondal D, Agrawal KC. Zidovudine (AZT) treatment suppresses granulocytemonocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells. Life Sci 2002;71(8):967-78.
13. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St. Claire ME, Poirier MC. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J Acquir Immune Defic Syndr 2002;29(4):323-9.
14. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004;20(1):91-100.
15. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004;199(2):151-61.
16. NTP Toxicology and Carcinogenesis Studies of Transplacental 3'-Azido-3'-Dioxythymidine (AZT) (CAS No. 30516-87-1) in Swiss (CD- 1(R)) Mice (in utero Studies). Natl Toxicol Program Tech Rep Ser 2006;(522):1-184.
17. Chan SS, Santos JH, Meyer JN, et al. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen 2007;48(3-4):190-200.
18. Divi RL, Leonard SL, Kuo MM, et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitorinduced mitochondrial toxicity. Environ Mol Mutagen 2007;48(3-4):201-9.
19. Martino M, Galli L, Tovo PA, et al for the Italian Register for HIV Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch Pediatr Adolesc Med 2002;156(9):915-21.
20. Thorne C, Patel D, Fiore S, Peckham C, Newell M; for the European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40(3):458-65.
21. Read JS; for The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340(13):977-87.
22. Kind C, Rudin C, Siegrist CA, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. Aids 1998;12(2):205-10.
23. Shah I. Is elective caesarean section really essential for prevention of mother to child transmission of HIV in the era of antiretroviral therapy and abstinence of breast feeding? J Trop Pediatr 2006;52(3):163-5.
24. Zhang Z, Diwan BA, Anderson LM, et al. Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3'- azido-2',3'-dideoxythymidine. Mol Carcinog 1998;23(1):45-51.
25. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3'-azido-3'-deoxythymidine in mice. Toxicol Appl Pharmacol 1999;161(1):82- 99.
26. Walker DM, Malarkey DE, Seilkop SK, et al. Transplacental carcinogenicity of 3'-azido-3'- deoxythymidine in B6C3F1 mice and F344 rats. Environ Mol Mutagen 2007;48(3-4):283-98.